Strategic News Service recently announced that Cynvenio Biosystems has been selected as a 2011 FiReStarter company, to be featured at its annual Future in Review technology conference.
Author: Global Cancer Consortium
Biovista announced recently that it has entered into a research collaboration agreement with Novartis.
WaferGen Biosystems is a leader in the development, manufacture, and sale of state-of-the-art systems for genome analysis for the life science and pharmaceutical industries.
Bio-Path Holdings has developed a powerful drug delivery technology that utilizes cell-like drug carriers, termed liposomes, which avoid drug breakdown.
In 2010, NCI estimated that 207,090 women were diagnosed with breast cancer, while 39,840 women likely died from the disease.
Parting is such sweet sorrow when building a company from infancy and then letting go to see it spread its wings. Planning a proper exit strategy is crucial and not just when referring to love and war.
ADVENTRX and SynthRx, a private biotechnology company, completed a definitive merger on April 8, 2011.
Ikonisys is a medical devices company that has developed a combinatorial technological platform using molecular biology and imaging methodology for the detection of rare cells, including cancer cells, and for the prenatal diagnosis of rare genetic disorders. The company’s proprietary cell-optics platform is an automated cell based diagnostic system that uses a highly sophisticated digital microscopy unit that can detect disease-specific cellular components and fluorescently labeled disease markers, enabling the detection and analysis of disease progression. The company has received FDA clearance for its fluorescent-based diagnostics of breast cancer, bladder cancer, and amniotic fluid prenatal genetic disorder screen. Fluorescent light-based…